This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kagamu, H. Articles by Shu, S. Search for Related Content PubMed PubMed Citation Articles by Kagamu, H. Articles by Shu, S.

Isolation Based on L-Selectin Expression of Immune Effector T Cells Derived from Tumor-draining Lymph Nodes¹

Center for Surgery Research, Division of Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio 44195

The ability to generate a large number of tumor-reactive T lymphocytes is the most critical requirement for adoptive immunotherapy. Our laboratory has previously demonstrated that cells from tumor-draining lymph nodes (LNs) are an excellent source of tumor-reactive T lymphocytes. After activation with anti-CD3, these cells readily proliferate in low concentrations of interleukin 2 and acquire effector functions. The adoptive transfer of these cells is capable of mediating the regression of tumors established in the lung as well as in the brain. Here, we analyzed several adhesion molecules on the tumor-draining LN T cells and separated them based on L-selectin expression. The homing receptor L-selectin mediates adhesion to the luminal surface of specialized high endothelial venules, thus regulating lymphocyte recirculation through peripheral LNs. In response to progressive tumor growth, a small population of draining LN T cells down-regulated L-selectin and increased the expression of CD44 and lymphocyte function-associated antigen 1. In adoptive immunotherapy, purified T cells with low L-selectin (L-selectin^-) expression constituted all the in vivo antitumor reactivity, whereas isolated high L-selectin (L-selectin⁺) cells were ineffective. Furthermore, reverse transcription-PCR analysis revealed that L-selectin^- cells expressed interleukin 2, IFN- and tumor necrosis factor mRNA upon in vitro stimulation with specific tumor cells. These results suggest that highly potent immune T cells can be isolated based on their pattern of adhesion molecule expression. The ability of the immune effector cells to transcribe cytokine genes when stimulated with tumor cells provides a basis for identifying similar cells for adoptive immunotherapy of cancer in humans.

¹ This work was supported in part by USPHS Grants CA 58927 and CA 64687 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at the Center for Surgery Research, FF50, Division of Surgery. The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.

Received 6/21/96. Accepted 8/15/96.

This article has been cited by other articles:

				K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, et al. Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage Clin. Cancer Res., November 1, 2008; 14(21): 6770 - 6779. [Abstract] [Full Text] [PDF]

				L.-X. Wang, S. Shu, M. L. Disis, and G. E. Plautz Adoptive transfer of tumor-primed, in vitro activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response Blood, June 1, 2007; 109(11): 4865 - 4876. [Abstract] [Full Text] [PDF]

				L.-X. Wang, S. Shu, and G. E. Plautz Host Lymphodepletion Augments T Cell Adoptive Immunotherapy through Enhanced Intratumoral Proliferation of Effector Cells Cancer Res., October 15, 2005; 65(20): 9547 - 9554. [Abstract] [Full Text] [PDF]

				T. Hiura, H. Kagamu, S. Miura, A. Ishida, H. Tanaka, J. Tanaka, F. Gejyo, and H. Yoshizawa Both Regulatory T Cells and Antitumor Effector T Cells Are Primed in the Same Draining Lymph Nodes during Tumor Progression J. Immunol., October 15, 2005; 175(8): 5058 - 5066. [Abstract] [Full Text] [PDF]

				J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion Cancer Res., December 15, 2004; 64(24): 9124 - 9130. [Abstract] [Full Text] [PDF]

				F. Ito, Q. Li, A. B. Shreiner, R. Okuyama, M. N. Jure-Kunkel, S. Teitz-Tennenbaum, and A. E. Chang Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines Cancer Res., November 15, 2004; 64(22): 8411 - 8419. [Abstract] [Full Text] [PDF]

				M. G. Sauer, M. E. Ericson, B. J. Weigel, M. J. Herron, A. Panoskaltsis-Mortari, B. T. Kren, B. L. Levine, J. S. Serody, C. H. June, P. A. Taylor, et al. A Novel System for Simultaneous in Vivo Tracking and Biological Assessment of Leukemia Cells and ex Vivo Generated Leukemia-Reactive Cytotoxic T Cells Cancer Res., June 1, 2004; 64(11): 3914 - 3921. [Abstract] [Full Text] [PDF]

				L.-X. Wang, J. Kjaergaard, P. A. Cohen, S. Shu, and G. E. Plautz Memory T Cells Originate from Adoptively Transferred Effectors and Reconstituting Host Cells after Sequential Lymphodepletion and Adoptive Immunotherapy J. Immunol., March 15, 2004; 172(6): 3462 - 3468. [Abstract] [Full Text] [PDF]

				B. J. Chen, X. Cui, G. D. Sempowski, C. Liu, and N. J. Chao Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease Blood, February 15, 2004; 103(4): 1534 - 1541. [Abstract] [Full Text] [PDF]

				S. Watanabe, H. Kagamu, H. Yoshizawa, N. Fujita, H. Tanaka, J. Tanaka, and F. Gejyo The Duration of Signaling through CD40 Directs Biological Ability of Dendritic Cells to Induce Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5828 - 5836. [Abstract] [Full Text] [PDF]

				L. Peng, J. Kjaergaard, G. E. Plautz, M. Awad, J. A. Drazba, S. Shu, and P. A. Cohen Tumor-Induced L-Selectinhigh Suppressor T Cells Mediate Potent Effector T Cell Blockade and Cause Failure of Otherwise Curative Adoptive Immunotherapy J. Immunol., November 1, 2002; 169(9): 4811 - 4821. [Abstract] [Full Text] [PDF]

				L.-X. Wang, B.-G. Chen, and G. E. Plautz Adoptive Immunotherapy of Advanced Tumors with CD62 L-Selectinlow Tumor-Sensitized T Lymphocytes Following Ex Vivo Hyperexpansion J. Immunol., September 15, 2002; 169(6): 3314 - 3320. [Abstract] [Full Text] [PDF]

				J. Kjaergaard, L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu Augmentation Versus Inhibition: Effects of Conjunctional OX-40 Receptor Monoclonal Antibody and IL-2 Treatment on Adoptive Immunotherapy of Advanced Tumor J. Immunol., December 1, 2001; 167(11): 6669 - 6677. [Abstract] [Full Text] [PDF]

				N. Fujita, H. Kagamu, H. Yoshizawa, K. Itoh, H. Kuriyama, N. Matsumoto, T. Ishiguro, J. Tanaka, E. Suzuki, H. Hamada, et al. CD40 Ligand Promotes Priming of Fully Potent Antitumor CD4+ T Cells in Draining Lymph Nodes in the Presence of Apoptotic Tumor Cells J. Immunol., November 15, 2001; 167(10): 5678 - 5688. [Abstract] [Full Text] [PDF]

				L. Peng, J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-{gamma} Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics J. Immunol., December 15, 2000; 165(12): 7116 - 7124. [Abstract] [Full Text] [PDF]

				L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression J. Immunol., November 15, 2000; 165(10): 5738 - 5749. [Abstract] [Full Text] [PDF]

				G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors J. Immunol., October 1, 2000; 165(7): 3656 - 3662. [Abstract] [Full Text] [PDF]

				J. Kjaergaard and S. Shu Tumor Infiltration by Adoptively Transferred T Cells Is Independent of Immunologic Specificity but Requires Down-Regulation of L-Selectin Expression J. Immunol., July 15, 1999; 163(2): 751 - 759. [Abstract] [Full Text] [PDF]

				M. J. Dobrzanski, J. B. Reome, and R. W. Dutton Therapeutic Effects of Tumor-Reactive Type 1 and Type 2 CD8+ T Cell Subpopulations in Established Pulmonary Metastases J. Immunol., June 1, 1999; 162(11): 6671 - 6680. [Abstract] [Full Text] [PDF]

				M. Korbelik and G. J. Dougherty Photodynamic Therapy-mediated Immune Response against Subcutaneous Mouse Tumors Cancer Res., April 1, 1999; 59(8): 1941 - 1946. [Abstract] [Full Text] [PDF]

				H. Tanaka, H. Yoshizawa, Y. Yamaguchi, K. Ito, H. Kagamu, E. Suzuki, F. Gejyo, H. Hamada, and M. Arakawa Successful Adoptive Immunotherapy of Murine Poorly Immunogenic Tumor with Specific Effector Cells Generated from Gene-Modified Tumor-Primed Lymph Node Cells J. Immunol., March 15, 1999; 162(6): 3574 - 3582. [Abstract] [Full Text] [PDF]

				H.-M. Hu, W. J. Urba, and B. A. Fox Gene-Modified Tumor Vaccine with Therapeutic Potential Shifts Tumor-Specific T Cell Response from a Type 2 to a Type 1 Cytokine Profile J. Immunol., September 15, 1998; 161(6): 3033 - 3041. [Abstract] [Full Text] [PDF]

				H. Kagamu and S. Shu Purification of L-Selectinlow Cells Promotes the Generation of Highly Potent CD4 Antitumor Effector T Lymphocytes J. Immunol., April 1, 1998; 160(7): 3444 - 3452. [Abstract] [Full Text] [PDF]